424 related articles for article (PubMed ID: 23117294)
1. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer.
Sasagawa T; Takagi H; Makinoda S
J Infect Chemother; 2012 Dec; 18(6):807-15. PubMed ID: 23117294
[TBL] [Abstract][Full Text] [Related]
2. Immunity to oncogenic human papillomaviruses.
Konya J; Dillner J
Adv Cancer Res; 2001; 82():205-38. PubMed ID: 11447764
[TBL] [Abstract][Full Text] [Related]
3. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.
de Jong A; van Poelgeest MI; van der Hulst JM; Drijfhout JW; Fleuren GJ; Melief CJ; Kenter G; Offringa R; van der Burg SH
Cancer Res; 2004 Aug; 64(15):5449-55. PubMed ID: 15289354
[TBL] [Abstract][Full Text] [Related]
5. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
[TBL] [Abstract][Full Text] [Related]
6. [Immune response in cervical cancer. Strategies for the development of therapeutic vaccines].
Mora-García ML; Monroy-García A
Rev Med Inst Mex Seguro Soc; 2015; 53 Suppl 2():S206-11. PubMed ID: 26462518
[TBL] [Abstract][Full Text] [Related]
7. [Escape mechanisms to the innate immune response in HPV-associated cervical cancer].
del Toro-Arreola S; García-Chagollán M; Jave-Suárez LF
Rev Med Inst Mex Seguro Soc; 2015; 53 Suppl 2():S194-9. PubMed ID: 26462516
[TBL] [Abstract][Full Text] [Related]
8. HPV: from infection to cancer.
Stanley MA; Pett MR; Coleman N
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1456-60. PubMed ID: 18031245
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
[TBL] [Abstract][Full Text] [Related]
10. Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women.
Zehbe I; Mytilineos J; Wikström I; Henriksen R; Edler L; Tommasino M
Hum Immunol; 2003 May; 64(5):538-42. PubMed ID: 12691704
[TBL] [Abstract][Full Text] [Related]
11. HPV innate immunity.
Woodworth CD
Front Biosci; 2002 Oct; 7():d2058-71. PubMed ID: 12165480
[TBL] [Abstract][Full Text] [Related]
12. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
Welters MJ; de Jong A; van den Eeden SJ; van der Hulst JM; Kwappenberg KM; Hassane S; Franken KL; Drijfhout JW; Fleuren GJ; Kenter G; Melief CJ; Offringa R; van der Burg SH
Cancer Res; 2003 Feb; 63(3):636-41. PubMed ID: 12566307
[TBL] [Abstract][Full Text] [Related]
13. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients.
Valdespino V; Gorodezky C; Ortiz V; Kaufmann AM; Roman-Basaure E; Vazquez A; Berumen J
Gynecol Oncol; 2005 Jan; 96(1):92-102. PubMed ID: 15589586
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III.
Nimako M; Fiander AN; Wilkinson GW; Borysiewicz LK; Man S
Cancer Res; 1997 Nov; 57(21):4855-61. PubMed ID: 9354449
[TBL] [Abstract][Full Text] [Related]
15. Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia.
Sheu BC; Chang WC; Lin HH; Chow SN; Huang SC
J Obstet Gynaecol Res; 2007 Apr; 33(2):103-13. PubMed ID: 17441881
[TBL] [Abstract][Full Text] [Related]
16. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
17. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
18. hrHPV E5 oncoprotein: immune evasion and related immunotherapies.
de Freitas AC; de Oliveira THA; Barros MR; Venuti A
J Exp Clin Cancer Res; 2017 May; 36(1):71. PubMed ID: 28545552
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.
Liu DW; Yang YC; Lin HF; Lin MF; Cheng YW; Chu CC; Tsao YP; Chen SL
J Virol; 2007 Mar; 81(6):2869-79. PubMed ID: 17202211
[TBL] [Abstract][Full Text] [Related]
20. The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma.
Berti FCB; Pereira APL; Cebinelli GCM; Trugilo KP; Brajão de Oliveira K
Cytokine Growth Factor Rev; 2017 Apr; 34():1-13. PubMed ID: 28365229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]